Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
FULC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.86 - $12.40
Previous CloseN/A
Volume345.04K
Average Volume (3M)393.76K
Market Cap
$160.32M
Enterprise Value-$25.29M
Total Cash (Recent Filing)$72.80M
Total Debt (Recent Filing)$30.00K
Price to Earnings (P/E)―
Beta0.89
Next Earnings
May 19, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding53,979,305
10 Day Avg. Volume440,841
30 Day Avg. Volume393,757
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.12
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.32
Enterprise Value/Ebitda2.55
Forecast
1Y Price Target
$5.67Price Target Upside90.91% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Fulcrum Therapeutics News
PremiumCompany Announcements
Fulcrum Therapeutics Faces Termination of Key Agreement
PremiumCompany Announcements
Fulcrum Therapeutics’ Earnings Call Highlights Financial Gains
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial EnrollmentThe withdrawal of Oxbryta has made it simpler to enroll patients, easing recruitment for FULC's study.
Market OpportunityGiven the withdrawal of OXBRYTA (voxelotor) from the market, pociredir has the potential to be a replacement and a superior alternative among oral treatments.
Bears Say
Study ComplicationsPatients being recruited in the 12mg dose cohort tend to have more disease severity, which could complicate the study outcomes.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.86 and its highest was $12.40 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $160.32M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is May 19, 2025 which is in 68 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Feb 25, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.282 by -$0.028.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 53,979,305 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.282. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Currently, no hedge funds are holding shares in FULC
---
Fulcrum Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.67 (90.91% Upside)
$5.67 (90.91% Upside)
Blogger Sentiment
Bullish
FULC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.19%
12-Months-Change
Fundamentals
Return on Equity
-4.07%
Trailing 12-Months
Asset Growth
1.17%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
---
FULC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights positive financial management with a strengthened cash position and reduced net loss, alongside promising progress in the sickle cell disease program. However, the lack of collaboration revenue in Q4 and restructuring costs present challenges. The sentiment is balanced with meaningful progress and ongoing challenges.Read More>---
FULC Stock 12 Month Forecast
Average Price Target
$5.67
▲(90.91% Upside)
Technical Analysis
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Editas Medicine
―
Crispr Therapeutics AG
―
Best Analysts Covering FULC
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
-10.55%
reiterated a sell rating 15 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -10.55% per trade.
---